These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8045754

  • 1. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 2. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Aug; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 3. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Aug; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 5. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Jan; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 6. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 8. [Therapeuetic management of patients with thalassemia major].
    Thuret I.
    Bull Soc Pathol Exot; 2001 May 21; 94(2):95-7. PubMed ID: 11475036
    [Abstract] [Full Text] [Related]

  • 9. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 May 21; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 10. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb 21; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 11. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 21; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 12. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.
    N Engl J Med; 1985 Jun 20; 312(25):1600-3. PubMed ID: 4000198
    [Abstract] [Full Text] [Related]

  • 13. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Jun 20; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 14. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Jun 20; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 15. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug 20; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 16. Central venous line thrombosis in children and young adults with thalassemia major.
    Finkelstein Y, Yaniv I, Berant M, Zilber R, Garty BZ, Epstein O, Lahav J, Tamary H.
    Pediatr Hematol Oncol; 2004 Aug 20; 21(5):375-81. PubMed ID: 15205080
    [Abstract] [Full Text] [Related]

  • 17. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct 20; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 18. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H, Garallahi F, Amini R.
    Pediatr Hematol Oncol; 2008 Sep 20; 25(6):502-8. PubMed ID: 18728969
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
    Yarali N, Fişgin T, Duru F, Kara A, Ecin N, Fitoz S, Erden I.
    J Pediatr Hematol Oncol; 2006 Jan 20; 28(1):11-6. PubMed ID: 16394886
    [Abstract] [Full Text] [Related]

  • 20. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
    Cavallaro L, Meo A, Busà G, Coglitore A, Sergi G, Satullo G, Donato A, Calabrò MP, Miceli M.
    Minerva Cardioangiol; 1993 Jan 20; 41(7-8):297-301. PubMed ID: 8233011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.